ライフサイエンスコーパス: acute ischemic stroke

1 r conventional treatment (control group) for acute ischemic stroke.

2 16, and received mechanical thrombectomy for acute ischemic stroke.

3 ssion levels are differentially regulated in acute ischemic stroke.

4 ve prothrombolytic potential in treatment of acute ischemic stroke.

5 y of a translational thromboembolic model of acute ischemic stroke.

6 t of endovascular treatment in patients with acute ischemic stroke.

7 ground breaking changes in the treatment of acute ischemic stroke.

8 mbra from the ischemic core in patients with acute ischemic stroke.

9 protect neonatal brain from hemorrhage after acute ischemic stroke.

10 ssociation between serum UA and prognosis of acute ischemic stroke.

11 e, which might become useful in treatment of acute ischemic stroke.

12 n M2 occlusions in a cohort of patients with acute ischemic stroke.

13 atelet therapy before tPA administration for acute ischemic stroke.

14 udy from the China Antihypertensive Trial in Acute Ischemic Stroke.

15 was seen in 68 (3.5%) of 1,931 patients with acute ischemic stroke.

16 C potentiates neuroinflammatory responses to acute ischemic stroke.

17 arct size in acute myocardial infarction and acute ischemic stroke.

18 Administration in 1996 for the treatment of acute ischemic stroke.

19 after usual care versus usual care alone for acute ischemic stroke.

20 ients and providers in considering r-tPA for acute ischemic stroke.

21 quitous but poorly understood consequence of acute ischemic stroke.

22 ombolysis remains the mainstay treatment for acute ischemic stroke.

23 tributor to delays in timely tPA therapy for acute ischemic stroke.

24 me to thrombolysis is crucial for outcome in acute ischemic stroke.

25 TN) time within 60 minutes for patients with acute ischemic stroke.

26 ht of the severe underuse of thrombolysis in acute ischemic stroke.

27 They had the signature features of acute ischemic stroke.

28 ta on its impact in endovascular therapy for acute ischemic stroke.

29 that can decrease ITN time for patients with acute ischemic stroke.

30 at discharge and discharge to home following acute ischemic stroke.

31 ed to translate to efficacious therapies for acute ischemic stroke.

32 outcome in patients treated with IV tPA for acute ischemic stroke.

33 meningeal collateral status in patients with acute ischemic stroke.

34 n and extend the therapeutic time window for acute ischemic stroke.

35 meningeal collateral status in patients with acute ischemic stroke.

36 essment as a neuroprotective agent following acute ischemic stroke.

37 alteplase is the only approved treatment for acute ischemic stroke.

38 anaging hypertensive patients suffering from acute ischemic stroke.

39 ntriguing treatment options in patients with acute ischemic stroke.

40 to improve the timeliness of reperfusion in acute ischemic stroke.

41 adults (aged 15-44 years) hospitalized with acute ischemic stroke.

42 d may represent up to two-thirds of cases of acute ischemic stroke.

43 ) is used for the treatment of patients with acute ischemic stroke.

44 iew of the state of the art of management of acute ischemic stroke.

45 the gold standard for penumbra detection in acute ischemic stroke.

46 important for sustaining tissue viability in acute ischemic stroke.

47 t be withheld in these complex patients with acute ischemic stroke.

48 uPAR promotes neurological recovery after an acute ischemic stroke.

49 rovide neuroprotection in an animal model of acute ischemic stroke.

50 ecommended strategies to reduce DTN times in acute ischemic stroke.

51 lity and functional outcome in patients with acute ischemic stroke.

52 compared with alteplase for the treatment of acute ischemic stroke, 1 that demonstrated superiority o

53 Among 30,947 patients with acute ischemic stroke, 15,297 (49.4%) were admitted to d

54 e (38%), intracerebral hemorrhage (31%), and acute ischemic stroke (18%).

55 , we identified 554 ventilated patients with acute ischemic stroke (19%), 936 ventilated patients wit

56 Of all patients with acute ischemic stroke, 26% required ICU admission.

57 Of 29 618 patients with acute ischemic stroke, 283 (1.0%) were treated within 4.

58 a on 220 patients with DM who presented with acute ischemic stroke, 43 of whom were managed with and

59 Among patients with acute ischemic stroke, admission to a designated stroke

60 HSS documentation in 1 184 288 patients with acute ischemic stroke admitted to 1704 GWTG-Stroke hospi

61 d long-term mortality in older patients with acute ischemic stroke admitted to ICUs is lower than pre

62 ole of CD (cluster of differentiation)-84 in acute ischemic stroke after recanalization and to dissec

63 Timely reperfusion is critical in acute ischemic stroke (AIS) and ST-segment-elevation myo

64 plasminogen activator (tPA) in patients with acute ischemic stroke (AIS) are time dependent and guide

65 Acute Ischemic Stroke (AIS) can be cured by trombolytic

66 improves clinical outcomes in patients with acute ischemic stroke (AIS) caused by a large vessel occ

67 5.9 years +/- 12.3; range, 25-86 years) with acute ischemic stroke (AIS) due to middle cerebral arter

68 Thus, we assessed CA status of patients with acute ischemic stroke (AIS) during intravenous r-tPA the

69 A relevant proportion of patients with acute ischemic stroke (AIS) have elevated levels of card

70 ry (cICA) occlusion is a recognized cause of acute ischemic stroke (AIS) in sickle cell disease (SCD)

71 Acute ischemic stroke (AIS) is the leading cause of disa

72 fusion therapy for large vessel occlusion in acute ischemic stroke (AIS) is time dependent, but the e

73 The substantial clinical improvement in acute ischemic stroke (AIS) patients treated with mechan

74 ates of tPA use over time among hospitalized acute ischemic stroke (AIS) patients.

75 olized rabbits and clinical rating scores in acute ischemic stroke (AIS) patients; however, the cellu

76 on between thyroid hormones and prognosis of acute ischemic stroke (AIS) reported conflicting results

77 Patients with acute ischemic stroke (AIS) suffer from infections assoc

78 acerebral hemorrhage (sICH) in patients with acute ischemic stroke (AIS) treated with intravenous thr

79 lycemia (aHG) with outcomes of patients with acute ischemic stroke (AIS) treated with intravenous thr

80 is known as to whether long-term outcomes of acute ischemic stroke (AIS) vary by race/ethnicity.

81 al thrombectomy (MT) is recommended to treat acute ischemic stroke (AIS) with a large vessel occlusio

82 factor for coronary artery disease (CAD) and acute ischemic stroke (AIS), but there are numerous repo

83 They are also frequently observed after acute ischemic stroke (AIS), indicating poor functional

84 e TSC is a promising drug candidate to treat acute ischemic stroke (AIS), we tested the hypothesis th

85 ted with better neurologic outcome following acute ischemic stroke (AIS).

86 a promising alternative for the treatment of acute ischemic stroke (AIS).

87 timating clinical outcomes for patients with acute ischemic stroke (AIS).

88 issue plasminogen activator (tPA) therapy in acute ischemic stroke (AIS).

89 window from 3 to 4.5 hours for patients with acute ischemic stroke (AIS).

90 efficient use of intravenous thrombolysis in acute ischemic stroke (AIS).

91 ravenous thrombolysis (IVT) in patients with acute ischemic stroke, although this appraisal is not ev

92 Patients who presented with acute ischemic stroke and a large vessel occlusion in th

93 There were 187 patients with acute ischemic stroke and continuous heart rhythm monito

94 all phase 3 trials of medical treatments for acute ischemic stroke and corresponding early clinical a

95 gnettes in which they had either suffered an acute ischemic stroke and could be treated with thrombol

96 e been receiving antiplatelet therapy before acute ischemic stroke and could face an increased risk f

97 terpretation of magnetic resonance images of acute ischemic stroke and how they are used to select pa

98 Among patients with acute ischemic stroke and hyperglycemia, treatment with

99 e observational study of 94474 patients with acute ischemic stroke and known history of AF admitted f

100 ta in 100 patients with anterior-circulation acute ischemic stroke and large vessel occlusion who und

101 essful revascularization among patients with acute ischemic stroke and large vessel occlusion.

102 Medical Center in Nashville, Tennessee, with acute ischemic stroke and later received a diagnosis of

103 Outcomes for some patients with acute ischemic stroke and moderate to severe neurologica

104 with faster thrombolytic treatment times for acute ischemic stroke and modestly lower 1-year all-caus

105 hanical thrombectomy in select patients with acute ischemic stroke and proximal artery occlusions has

106 urrent stroke and cardiovascular outcomes in acute ischemic stroke and transient ischemic attack (TIA

107 re most likely to benefit from therapies for acute ischemic stroke and whether endovascular thrombect

108 All 3 patients presented with acute ischemic strokes and had a history of epidural spi

109 Patients with acute ischemic strokes and LVO in M2 segments presenting

110 rospective cohort study pooled patients with acute ischemic strokes and LVO isolated to M2 segments f

111 critical limb ischemia, pulmonary embolism, acute ischemic stroke, and acute aortic syndromes.

112 ave evaluated hypothermia as a treatment for acute ischemic stroke, and no controlled trials of hypot

113 ition, emergency interventional treatment of acute ischemic stroke, and treatment in dedicated stroke

114 All patients with acute ischemic stroke are in need of hyperacute secondar

115 s tissue-type plasminogen activator (tPA) in acute ischemic stroke are time dependent, and guidelines

116 venous tissue-plasminogen activator (tPA) in acute ischemic stroke are time-dependent.

117 Acute ischemic strokes are associated with poor outcomes

118 iving intravenous thrombolytic treatment for acute ischemic stroke at 1490 Get With The Guidelines-St

119 olesterol efflux capacity) in patients after acute ischemic stroke at 2 time points (24 hours, 35 pat

120 estigate the outcomes of patients who had an acute ischemic stroke attributed to an anterior circulat

121 is decisions for incapacitated patients with acute ischemic stroke because the risks and benefits of

122 Among patients with acute ischemic stroke, black patients had lower mortalit

123 of endovascular therapy to standard care for acute ischemic stroke, but pointed out to the need and d

124 rtension are correlated with poor outcome in acute ischemic stroke, but the effect of reducing or aug

125 (t-PA) for patients with moderate-to-severe acute ischemic stroke, but whether a combined approach i

126 for Medicare beneficiaries hospitalized with acute ischemic stroke, but whether it is necessary to in

127 ovide neuroprotection in mechanical model of acute ischemic stroke by inducing hypothermia, a conditi

128 Acute ischemic stroke care provides a useful application

129 METHODS AND Acute ischemic stroke cases entered into GWTG (Get With

130 te door-to-needle time reductions (5057 more acute ischemic stroke cases/y in the 0-3-hour window) in

131 In patients with acute ischemic stroke caused by a proximal intracranial

132 In patients with acute ischemic stroke caused by a proximal intracranial

133 Intra-arterial treatment (IAT) for acute ischemic stroke caused by intracranial arterial oc

134 favorable clinical outcomes in patients with acute ischemic stroke caused by intracranial proximal oc

135 ciated with better outcomes in patients with acute ischemic stroke caused by large artery occlusion.

136 Acute ischemic stroke caused by proximal intracranial ar

137 An algorithm using only acute ischemic stroke codes (433.x1, 434.x1, 436) had a

138 trials comparing endovascular treatment for acute ischemic stroke compared to the previous standard

139 ke risk factors among those hospitalized for acute ischemic stroke continued to increase from 2003-20

140 The clusters identified show promise for acute ischemic stroke detection.

141 The majority of patients with acute ischemic stroke do not receive any form of reperfu

142 We analyzed 1,986 patients with acute ischemic stroke due to anterior circulation large

143 of symptomatic carotid web in patients with acute ischemic stroke due to intracranial large vessel o

144 In acute ischemic stroke due to large artery occlusion, mec

145 n were observed in 2.5% of the patients with acute ischemic stroke due to large vessel occlusion and

146 In patients receiving intravenous t-PA for acute ischemic stroke due to occlusions in the proximal

147 Among patients with acute ischemic stroke due to occlusions in the proximal

148 onsiderations of intra-arterial treatment of acute ischemic stroke emphasizes the need for well desig

149 0 045 consecutive emergency department-based acute ischemic stroke encounters arriving </= 3 hours af

150 Among patients with acute ischemic stroke, endovascular therapy with mechani

151 patients aged 18 to 45 years with first-ever acute ischemic stroke enrolled in the multicenter Italia

152 For acute ischemic stroke, fibrinolysis is the only treatmen

153 ator has been a cornerstone for treatment of acute ischemic stroke for more than 20 years; however, i

154 However, 23% to 40% of ideal candidates with acute ischemic stroke for reperfusion are not treated, p

155 has been the key treatment for patients with acute ischemic stroke for the past decade.

156 th CT angiography examinations for suspected acute ischemic stroke from February 2017 to June 2018.

157 of a telestroke network in the management of acute ischemic stroke from the perspectives of a network

158 plasminogen activator (tPA) in patients with acute ischemic stroke, guidelines recommend door-to-imag

159 ndovascular treatment (EVT) in patients with acute ischemic stroke has an effect on the functional ou

160 General anesthesia during thrombectomy for acute ischemic stroke has been associated with poor neur

161 The treatment of acute ischemic stroke has undergone dramatic changes rec

162 Recent clinical trials in adults with acute ischemic stroke have demonstrated increased mortal

163 Several trials involving patients with acute ischemic stroke have shown better functional outco

164 indings in this study are as follows: first, acute ischemic stroke hospitalization rates increased si

165 health risk behaviors were identified among acute ischemic stroke hospitalizations in young adults.

166 the only existing strategy for patients with acute ischemic stroke, however it causes further brain d

167 Endovascular intervention for acute ischemic stroke improves revascularization.

168 oral trends, and early clinical outcomes for acute ischemic stroke in a large contemporary cohort.

169 is the first trial of a neuroprotectant for acute ischemic stroke in a trial design allowing thrombe

170 We conclude that RIC in the setting of acute ischemic stroke in rats is safe, reduces infarct s

171 anical thrombectomy with stent retrievers in acute ischemic stroke in the anterior circulation in ter

172 nclusions and Relevance: Among patients with acute ischemic stroke in the anterior circulation underg

173 14-February 2016) included 150 patients with acute ischemic stroke in the anterior circulation, highe

174 Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) in w

175 Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands (MR CLEAN) was

176 Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN).

177 Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands.

178 clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands.

179 Thrombolysis for acute ischemic stroke in the unwitnessed or extended the

180 tion of increasing hospitalization rates for acute ischemic stroke in young adults coexistent with in

181 h atrial fibrillation who had experienced an acute ischemic stroke, inadequate therapeutic anticoagul

182 advances in the treatment and prevention of acute ischemic stroke, including the current state of en

183 study, the prevalence of hospitalizations of acute ischemic stroke increased among all age and gender

184 issue plasminogen activator (IV tPA) use for acute ischemic stroke increased in Massachusetts in asso

185 The results of this trial in patients with acute ischemic stroke indicate that endovascular therapy

186 Consecutive patients with acute ischemic stroke initially admitted to a non-thromb

187 Among patients with acute ischemic stroke involving the anterior circulation

188 Acute ischemic stroke is a leading cause of serious disa

189 chemic stroke is rapidly developing.Although acute ischemic stroke is a major cause of adult disabili

190 Acute ischemic stroke is a major cause of mortality and

191 Acute ischemic stroke is a severe and life-threatening d

192 Acute ischemic stroke is associated with high concentrat

193 venous tissue plasminogen activator (tPA) in acute ischemic stroke is associated with reduced mortali

194 Hyperglycemia during acute ischemic stroke is common and is associated with w

195 sedation and airway during thrombectomy for acute ischemic stroke is controversial due to lack of ev

196 A specific cohort of suspected acute ischemic stroke is employed and it is found that 9

197 The management of acute ischemic stroke is rapidly developing.Although acu

198 Intravenous thrombolysis (IVT) for acute ischemic stroke is subject to label and guideline

199 Endovascular thrombectomy (ET) for acute ischemic stroke is the current standard of care.

200 Acute ischemic stroke is the leading cause of disability

201 efit of intravenous thrombolytic therapy for acute ischemic stroke is time dependent.

202 effectiveness of intravenous thrombolysis in acute ischemic stroke is time dependent.

203 s tissue-type plasminogen activator (tPA) in acute ischemic stroke is time dependent.

204 The treatment of acute ischemic stroke is very similar to acute myocardia

205 d-based biomarkers with clinical utility for acute ischemic stroke (IS).

206 ) is associated with reduced mortality after acute ischemic stroke, less is known about severe obesit

207 iterature regarding anesthetic management in acute ischemic stroke lies in the sedation level.

208 VIEW: Efforts in intra-arterial treatment of acute ischemic stroke mainly focus on new devices to rep

209 Intravenous thrombolysis is the mainstay of acute ischemic stroke management for any patient with di

210 We applied this framework to an acute ischemic stroke microsimulation model to calculate

211 with diabetes mellitus (DM) presenting with acute ischemic stroke might influence the incidence of H

212 hibits remarkable neuroprotection in a mouse acute ischemic stroke model.

213 ompared mortality for patients admitted with acute ischemic stroke (n = 30,947) between 2005 and 2006

214 Patients with acute ischemic stroke (n=1791) >/=45 years were identifi

215 hin and outside of the Remote Evaluation for Acute Ischemic Stroke network: tPA (tissue-type plasmino

216 tially benefit from endovascular therapy for acute ischemic stroke, nor was embolectomy shown to be s

217 All patients hospitalized with acute ischemic stroke or intracerebral hemorrhage in a l

218 Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA.

219 For tPA payments in acute ischemic stroke, our model-based results suggest f

220 Consecutive acute ischemic stroke patients (1,645 patients; Acute ST

221 m that treatment disparities exist for older acute ischemic stroke patients and that the rates of thr

222 he neurologic deficit and quality of life of acute ischemic stroke patients and that the therapeutic

223 of life and brain functional connectivity in acute ischemic stroke patients and to explore the mechan

224 Acute ischemic stroke patients are at risk of acute kidn

225 Data from acute ischemic stroke patients treated with tPA within 3

226 he occurrence rate of acute kidney injury in acute ischemic stroke patients was low and was not highe

227 A total of 194 samples from 76 acute ischemic stroke patients were analyzed.

228 One third of acute ischemic stroke patients were functionally depende

229 In total, 44 acute ischemic stroke patients were randomly divided to

230 Twenty-nine acute ischemic stroke patients were scanned with a media

231 INTRODUCTION: We aimed to identify whether acute ischemic stroke patients with known complete reper

232 issue-type plasminogen activator; IV tPA) in acute ischemic stroke patients with prior ischemic strok

233 ular therapy is an appropriate treatment for acute ischemic stroke patients within the t-PA window wh

234 Of 4782 acute ischemic stroke patients, 282 were underweight (BM

235 Baseline UA levels were measured in 3284 acute ischemic stroke patients.

236 travenous thrombolysis) in the management of acute ischemic stroke patients.

237 ctors associated with acute kidney injury in acute ischemic stroke patients.

238 ased the risk of death within 3 months among acute ischemic stroke patients.

239 e performing mechanical thrombectomy (MT) in acute ischemic stroke patients.

240 bectomy with the use of a stent retriever in acute ischemic stroke, performed by using a balloon guid

241 ood samples were drawn from 10 patients with acute ischemic stroke presenting within 24 h of symptom

242 We conclude that, in diabetic patients with acute ischemic stroke, prior and continued use of SU dru

243 program, known as the Remote Evaluation for Acute Ischemic Stroke program, has been implemented in G

244 of the literature relating to reperfusion in acute ischemic stroke published within the last year pro

245 DTN times for tPA treatment in patients with acute ischemic stroke remain suboptimal.

246 e stent retriever technique in patients with acute ischemic stroke remain uncertain because of lack o

247 ween serum uric acid (UA) and outcomes after acute ischemic stroke remains debatable in human studies

248 Patients with acute ischemic stroke require immediate diagnostic worku

249 nt is now the new standard for patients with acute ischemic stroke resulting from proximal vessel occ

250 l patients to the diagnosis and prognosis of acute ischemic stroke, septic shock, lung injuries, insu

251 nistration-approved thrombolytic therapy for acute ischemic stroke since 1996, thrombolysis remains u

252 ogen activator, the only approved therapy of acute ischemic stroke still remains unknown.

253 Studies of anesthesia for acute ischemic stroke suggested that inadequate brain pe

254 ectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial in patients wi

255 e series or case reports of patients with an acute ischemic stroke that evaluated a neurothrombectomy

256 uited patients aged older than 49 years with acute ischemic stroke that was restricted to the territo

257 n patients with atrial fibrillation (AF) and acute ischemic stroke, the association of prior anticoag

258 a clinical perspective for the treatment of acute ischemic stroke, these data suggest that helium 1)

259 activator (r-tPA) in eligible patients with acute ischemic stroke to improve patients' functional re

260 ithin 8 hours after the onset of symptoms of acute ischemic stroke to receive either medical therapy

261 e 2013 guidelines on the early management of acute ischemic strokes to specifically incorporate the f

262 We examined 371 988 patients with acute ischemic stroke transported by EMS and enrolled in

263 nt to prognosis in intracerebral hemorrhage, acute ischemic stroke, traumatic brain injury, subarachn

264 A cohort analysis of 1193 patients having acute ischemic stroke treated with intravenous tPA betwe

265 Among patients with an acute ischemic stroke treated with intravenous tPA, thos

266 door-to-needle (DTN) times in patients with acute ischemic stroke treated with tissue-type plasminog

267 ndovascular therapy is a promising aspect of acute ischemic stroke treatment.

268 IAS) and Dose Escalation of Desmoteplase for Acute Ischemic Stroke Trial (DEDAS), and (b) another req

269 derived from the successful Desmoteplase in Acute Ischemic Stroke Trial (DIAS) and Dose Escalation o

270 r time from onset to recanalization (OTR) in acute ischemic stroke using endovascular therapy (ET) ha

271 of 5hmC in blood samples from patients with acute ischemic stroke was also significantly increased.

272 Tissue plasminogen activator (tPA) for acute ischemic stroke was approved by the U.S. Food and

273 claims data for Medicare beneficiaries with acute ischemic stroke was associated with considerably i

274 nctional outcome at 2 years in patients with acute ischemic stroke was similar to that reported at 90

275 s Treated With Neurothrombectomy Devices for Acute Ischemic Stroke) was a prospective, multicenter, o

276 rgone 4D CT angiography for the suspicion of acute ischemic stroke were retrospectively identified.

277 Subjects with acute ischemic stroke were scanned with T2*-weighted MRI

278 death, acute myocardial infarction (AMI), or acute ischemic stroke, were evaluated over time.

279 y increased at 24 and 48 h in patients after acute ischemic stroke when compared to control values, w

280 endovascular therapy (EVT) in patients with acute ischemic stroke who have large vessel occlusion ha

281 rrhagic transformation (HT) in patients with acute ischemic stroke who receive intra-arterial thrombo

282 WIFT PRIME) trial in patients with disabling acute ischemic stroke who underwent endovascular therapy

283 or >=150 mg/dL if did not have diabetes) and acute ischemic stroke who were enrolled within 12 hours

284 Among patients aged 65 years or older with acute ischemic stroke who were treated with tissue plasm

285 Endovascular treatment for acute ischemic stroke with a large vessel occlusion was

286 Among patients with acute ischemic stroke with a proximal vessel occlusion,

287 n addition to standard care in patients with acute ischemic stroke with a small infarct core, a proxi

288 essity for rapid evaluation and treatment of acute ischemic stroke with intravenous tPA (tissue-type

289 aged 65 years or older who were treated for acute ischemic stroke with intravenous tPA within 4.5 ho

290 Individuals with acute ischemic stroke with ipsilateral carotid stenosis

291 Conclusion In the context of acute ischemic stroke with ipsilateral ICA nonattenuatio

292 To examine the prevalence of patients with acute ischemic stroke with known history of AF who were

293 ROCK activity is increased in patients after acute ischemic stroke with maximal activity occurring ab

294 arly valuable for treatment of patients with acute ischemic stroke with tissue plasminogen activator

295 In acute ischemic stroke with unknown time of onset, magnet

296 T) compared with best medical management for acute ischemic strokes with large vessel occlusion (LVO)

297 tween May 1, 2010, and October 1, 2012, with acute ischemic stroke within 4.5 hours from symptom onse

298 issue plasminogen activator in patients with acute ischemic stroke within 6 h of onset.

299 o had a magnetic resonance imaging-confirmed acute ischemic stroke within the anterior circulation an

300 We randomly assigned 362 patients with acute ischemic stroke, within 4.5 hours after onset, to